drugset / Trial / NCT02589301

Pharmacokinetics and Pharmacodynamics Comparison Study Between Two Pegfilgrastim Formulations

NCT02589301

Phase 1 Completed 100 enrolled Eurofarma Laboratorios S.A.
RandomizedParallel-groupOpen-labelOther

Summary

This study will evaluate the pharmacokinetics (relative bioavailability) and pharmacodynamics, after single subcutaneous application, in healthy volunteers of both sexes, between pegfilgrastim formulation, produced by Eurofarma Laboratorios S/A and Neulastim® (reference formulation), marketed by Produtos Roche Químicos e Farmacêuticos S/A. In addition to that, a pharmacodynamics comparison will be performed, through change in absolute neutrophil count in leukogram performed in the same time of pharmacokinetics analysis collection and through CD34+ cell count in peripheral blood at timepoints 0:00, 96:00 and 384:00 hours.

Timeline

Start
2015-11
Primary completion
2016-03
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegfilgrastim Protein / enzyme biologic 6 mg Subcutaneous

Indications